IOGULAMIDE

Details

Stereochemistry	MIXED
Molecular Formula	C20H26I3N3O12
Molecular Weight	881.1468
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 5
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OCC(O)CNC(=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(NC(=O)C(=O)[C@@H](O)[C@H](O)[C@@H](O)CO)=C1I

InChI

InChIKey=DFDJVFYYDGMDTB-BIYVAJLZSA-N

InChI=1S/C20H26I3N3O12/c21-11-9(18(36)24-1-6(30)3-27)12(22)14(13(23)10(11)19(37)25-2-7(31)4-28)26-20(38)17(35)16(34)15(33)8(32)5-29/h6-8,15-16,27-34H,1-5H2,(H,24,36)(H,25,37)(H,26,38)/t6?,7?,8-,15+,16-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C20H26I3N3O12
Molecular Weight	881.1468
Charge	0
Count

Stereochemistry	MIXED
Additional Stereochemistry	No
Defined Stereocenters	3 / 5
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6600337 | https://www.ncbi.nlm.nih.gov/pubmed/3198347 | https://www.ncbi.nlm.nih.gov/pubmed/15883920

Iogulamide is triiodobenzenedicarboxamide derivative patented by Mallinckrodt, Inc. as nonionic X-ray contrast agent for intrathecal use. Comparative preclinical animal studies demonstrated an acute safety profile significantly superior to that of metrizamide. Improved safety was unrelated to low osmolality. Intrathecally administered iogulamide produced no evidence of epileptogenic activity.

Originator

Approval Year

PubMed

Title	Date	PubMed

Patents

Substance Class	Chemical Created by `admin` on `Fri Dec 15 18:46:18 GMT 2023` Edited by `admin` on `Fri Dec 15 18:46:18 GMT 2023`
Record UNII	85615GZ318
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

IOGULAMIDE

Official Name

English

IOGULAMIDE [USAN]

Common Name

English

MP-10013

Code

English

1,3-BENZENEDICARBOXAMIDE, N,N'-BIS(2,3-DIHYDROXYPROPYL)-5-((L-XYLO-2-HEXULOSONOYL)AMINO)-2,4,6-TRIIODO-

Common Name

English

N,N'-BIS(2,3-DIHYDROXYPROPYL)-5-L-XYLO-2-HEXULOSONAMIDO-2,4,6-TRIIODOISOPHTHALAMIDE

Common Name

English

Code System Code Type Description

PUBCHEM

23724929